March 11, 2023New England Journal of Medicine803 citationsOpen Access
Fifteen-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer
View Full Paper
Key Points
Key points are not available for this paper at this time.
Abstract
After 15 years of follow-up, prostate cancer-specific mortality was low regardless of the treatment assigned. Thus, the choice of therapy involves weighing trade-offs between benefits and harms associated with treatments for localized prostate cancer. (Funded by the National Institute for Health and Care Research; ProtecT Current Controlled Trials number, ISRCTN20141297; ClinicalTrials.gov number, NCT02044172.).
Cite This Study
Hamdy et al. (2023) studied this question.